Amerikanische Gesellschaft für Hirudotherapie

The Effects of Dextran on Postoperative Thrombosis and Hemodilution in Microvascular Head and Neck Reconstruction.

Research article published in Annals of plastic surgery (2020)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Forschungsartikel – EvidenzreviewArtikelreferenz
Evidence: Research reportKlinische StudienArzneimittelentwicklungFilipan et al. · Annals of plastic surgery, 2020

Abstract

BACKGROUND: Free tissue transfer is an integral part of reconstructive head and neck surgery today. Although increased experience and refinements in techniques have minimized flap loss, pharmacological agents have been used to prevent thrombus formation and flap failures, despite their questionable effectiveness. The aim of this study is to investigate the use of dextran 40 in thrombosis prophylaxis, as well as its effects on blood coagulability and flap survival. METHODS: This is a retrospective analysis of 176 free flaps performed at University Hospital Dubrava, Zagreb, Croatia, during a 4-year period. A comparison was made between 2 patient groups, based on their respective postoperative prophylaxis protocols. All patients were treated with low-molecular-weight heparin as deep vein thrombosis prevention, until patient mobilization. Group 1 was on dextran 40 protocol, whereas group 2 did not receive additional treatment. Primary outcome of the study was determined as flap loss rate, whereas secondary outcome was evaluated as the rate of thrombosis or hemorrhage. The hemodilution potential of dextran 40 was examined through blood count laboratory values. RESULTS: Total flap survival rate was 90.34%. There were 16 free flap losses and 1 partial loss overall. Anastomoses were re-explored in a total of 27 cases, of which 17 were salvaged. There were 29 events of hemorrhage or arterial or venous thrombosis: 17 in group 1 and 12 in group 2. A sum of 26 incidences of other postoperative complications was recorded, 13 in each group. Hemodilution status showed a statistically significant reduction in erythrocyte count and hemoglobin and hematocrit levels in the group receiving dextran 40, on postoperative days 1 and 3, but no such effect was observed on postoperative platelet count. CONCLUSIONS: Although dextran 40 has been shown to have a valuable effect on hemodilution, which is beneficial in microsurgery, it did not demonstrate better outcomes in terms of flap survival. Because it can cause serious systemic complications, it is better not to administer it routinely. However, its important influence on reduction in erythrocyte count and hemoglobin and hematocrit levels should be further investigated.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansCroatiaDextransFree Tissue FlapsHead and Neck NeoplasmsHemodilutionMicrosurgeryPlastic Surgery ProceduresPostoperative ComplicationsRetrospective StudiesThrombosisTreatment Outcome

Zusammenfassung

Free tissue transfer is an integral part of reconstructive head and neck surgery today. Although increased experience and refinements in techniques have minimized flap loss, pharmacological agents have been used to prevent thrombus formation and flap failures, despite their questionable effectiveness.

Warum dies für die Hirudotherapie relevant ist

Diese retrospektive Studie untersucht den Einsatz von Dextran 40 zur postoperativen Thromboseprophylaxe und dessen Hämodilutionseffekte bei 176 mikrochirurgischen Kopf-Hals-Rekonstruktionsfällen. Die Ergebnisse zeigen, dass Dextran 40 zwar signifikant die Erythrozyten- und Hämoglobinwerte senkte, jedoch im Vergleich zur Kontrollgruppe keine Verbesserung der Lappenüberlebensraten bewirkte und Risiken schwerer systemischer Komplikationen barg. Diese Forschung ist kontextuell hochrelevant für ASH, da die mikrochirurgische Kopf-Hals-Rekonstruktion ein primäres chirurgisches Setting darstellt, in dem medizinische Blutegel zur Salvage-Therapie versagender Lappen aufgrund venöser Kongestion eingesetzt werden. Sie beleuchtet die anhaltenden klinischen Herausforderungen bei der Suche nach sicherer, wirksamer Antikoagulation in genau diesem chirurgischen Bereich. Die Studie selbst weist jedoch keine direkte Involvierung von Blutegeln oder Hirudotherapie auf.

Zitation

The Effects of Dextran on Postoperative Thrombosis and Hemodilution in Microvascular Head and Neck Reconstruction.

Filipan et al. · Annals of plastic surgery, 2020

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.